Aptevo raises about $3.0M as warrant holders exercise at reduced $1.08 price in inducement deal
Aptevo Therapeutics, a clinical-stage immuno-oncology company, agreed with existing warrant holders on November 12, 2026 to have them exercise 2,777,778 warrants for cash at a reduced $1.08 per share, generating roughly $3.0 million in gross proceeds. In return, holders will receive new unregistered inducement warrants for up to 13,888,890 shares at $1.08, exercisable after stockholder approval and expiring five years after first exercise. Roth Capital Partners advised on the deal, and Aptevo has agreed to file a resale registration statement with the SEC.
Company's press release (SEC filing): Aptevo Therapeutics Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M
Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597
Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants
Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities
Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds
